Colorectal cancer (CRC) risk estimates based on family history typically include only close relatives. We report familial relative risk (FRR) in probands with various combinations, or constellations, of affected relatives, extending to third-degree. METH-ODS: A population-based resource that includes a computerized genealogy linked to statewide cancer records was used to identify genetic relationships among CRC cases and their first-, second-, and third-degree relatives (FDRs, SDRs, and TDRs). FRRs were estimated by comparing the observed number of affected persons with a particular family history constellation to the expected number, based on cohort-specific CRC rates. RESULTS: A total of 2,327,327 persons included in Ն3 generation family histories were analyzed; 10,556 had a diagnosis of CRC. The FRR for CRC in persons with Ն1 affected FDR ϭ 2.05 (95% CI, 1.96 -2.14), consistent with published estimates. In the absence of a positive first-degree family history, considering both affected SDRs and TDRs, only 1 constellation had an FRR estimate that was significantly Ͼ1.0 (0 affected FDRs, 1 affected SDR, 2 affected TDRs; FRR ϭ 1.33; 95% CI, 1.13-1.55). The FRR for persons with 1 affected FDR, 1 affected SDR, and 0 affected TDRs was 1.88 (95% CI, 1.59 -2.20), increasing to FRR ϭ 3.28 (95% CI, 2.44 -4.31) for probands with 1 affected FDR, 1 affected SDR, and Ն3 affected TDRs. CONCLUSIONS: Increased numbers of affected FDRs influences risk much more than affected SDRs or TDRs. However, when combined with a positive first-degree family history, a positive second-and third-degree family history can significantly increase risk.
C olorectal cancer (CRC) is the third most common cancer diagnosed in the United States and the second leading cause of death among cancers. It is estimated that in 2008 alone 148,810 people will be diagnosed with CRC and 49,960 will die of the disease. 1 Screening strategies such as fecal occult blood test, flexible sigmoidoscopy, and colonoscopy, among others, have been proven effective in reducing the incidence and mortality of the disease. 2 Although CRC incidence and mortality rates have been declining, most US adults are still not being screened or receiving regular screenings appropriate for their age or risk status. 3, 4 Knowledge of increased risk can be a motivating factor in making decisions about screening. 5 If a greater proportion of adults received regular screenings appropriate for their risk, it is likely that additional reductions in CRC incidence and mortality could be achieved.
Family history is a well-established risk factor for CRC. 6 Many studies have estimated familial risk of CRC and consistently shown that having Ն1 affected firstdegree relative (FDR) doubles a person's risk of CRC. 6 -10 A recent random-effects analysis that pooled relative risk estimates for CRC from multiple published reports was presented by Butterworth et al in 2006 . 11 Although this meta-analysis comprehensively included the relevant published research to date, limitations in the source studies bring to light additional questions. Most studies focused on categorizing Ն1 affected FDR. Additional risk factors in other studies included affected second-degree relatives (SDRs), age of onset in affected FDRs, sex, and relationship type (ie, parent or child, sister or brother). Although data on FDRs are the easiest to obtain from patients and may be the most clinically relevant, it is currently not known what impact more distant affected relatives have on risk. Just as important, the risk stemming from various combinations, or "constellations," of affected relatives has not been adequately explored. Patients frequently present to physicians reporting multiple relatives affected with colorectal cancer. These often include affected relatives from first-, second-, and thirddegree relationships and might include positive family history from both parents (Figure 1 contains a pedigree diagram to show family relationships and degrees). Physicians presently have little if any data on how to estimate risk for such patients and thereby to determine appropriate screening.
The objective of our study was to expand the scope of previous CRC familial risk research to measure and report familial relative risk (FRR) estimates for a variety of specific constellations of family history. This investigation allows risk levels to be assigned for most combinations of affected relatives, thus assisting the physician in making more appropriate screening recommendations. To accomplish this we examined first-, second-, and third-degree risks in a population-based resource with a computerized genealogy linked to statewide cancer registry records. This resource, the Utah Population Database (UPDB), provides an unusual opportunity to investigate the relative risk of CRC in relatives in a large population at a more detailed level than has been previously published.
Data
The UPDB is a population-based, computerized genealogic resource for Utah containing multiple recordlinked data sources, including cancer registry records, birth and death certificates, and driver's license data, that has also been linked to inpatient and outpatient records from the University of Utah Health Sciences Center. The UPDB contains genealogies for the original Utah pioneers (members of The Church of Jesus Christ of Latterday Saints, or Mormons) and their modern-day descendants and was created in the early 1970s with data from the Utah Family History Library. 12, 13 The original Utah Genealogy included records for 1.6 million persons who were part of 6-to 7-generation pedigrees. 14 Today, the UPDB includes information for approximately 7 million persons, although not all have linked genealogic data. Some pedigrees are now Ͼ11 generations deep.
Of particular interest for this study were Utah Cancer Registry (UCR) records linked to the Utah genealogy. The UCR is a statewide cancer registry established in 1966 that includes records dating back to 1952. Since 1973 the UCR has been part of the Surveillance, Epidemiology, and End Results network of National Cancer Institute registries. Ninety-four percent of persons with cancer link to Ն1 records in the UPDB and 64.2% have family information. The UCR cancer records are coded by disease site according to the International Classification of Diseases of Oncology and include information on site, stage, grade, age at diagnosis, histology, and patient survival. 15 The UCR is careful to report only independent primary sites of cancer in cases in which a person has multiple cancers.
Previous demographic and genetic analyses have shown that the population recorded in the UPDB is genetically representative of US white and northern European populations 16 -19 with a low-to-normal level of inbreeding. 20 Most Utahns are members of The Church of Jesus Christ of Latter-day Saints, which has religious proscriptions against the use of coffee, tea, alcohol, and tobacco. Utah is among the states with the lowest rates of cancer, 1 and much lower smoking rates may play a role. 21 Although the UPDB contains records for approximately 7 million people, this study used a subset of 2.3 million persons who were part of Ն3 generations of Utah genealogy data and descendants of original Utah pioneers.
Access to the UPDB is governed by the Utah Resource for Genetic Epidemiology which was created in 1982. 22 The Utah Resource for Genetic Epidemiology and University of Utah Institutional Review Board approvals were obtained to access these data and to conduct this research. Names and other identifying information were not available to the authors to protect the privacy of persons in the UPDB.
Materials and Methods
FRR in relatives represents the ratio of the risk for a disease among relatives of probands to the risk for the disease in the general population. It is estimated as the number of observed (O) cases among relatives of probands divided by the number of expected (E) cases among the relatives (ie, FRR ϭ O/E). The expected number of cases among relatives is estimated by using population rates. This ratio, also known as a "standardized morbidity ratio," is considered a reasonable approximation of true relative risk when the prevalence of the disease and the true relative risk in the population are low. 23 This method of estimating FRR in relatives has been used in previous UPDB analyses of familial risk in cancer 24, 25 and other diseases. 26, 27 All persons in the UPDB who are part of Ն3 generations of Utah genealogy data (2.3 million) were assigned to 1 of 264 cohorts based on characteristics that may influence the quality and quantity of genealogic data: birth year (5-year groups), sex, amount of ancestral genealogy (Ͼ6 ancestors or not), and birthplace (Utah or not Utah). Internal, cohort-specific CRC rates were calculated by summing the number of CRC cases in each cohort and dividing by the total number of UPDB persons in that cohort. In this study a proband was defined as a person who has a particular constellation pattern of affected relatives (eg, 1 affected FDR, 0 affected SDRs, and Ն3 third-degree relatives [TDRs]), whether the proband is a CRC case himself or herself. All persons among the 2.3 million with a particular constellation pattern of affected relatives were considered probands for the corresponding FRR calculation.
After selecting a constellation pattern and determining the group of probands who fit the pattern, the number of observed CRC cases (O) in the group of probands is counted by cohort, without duplication. The expected number of cancers (E) among the defined set of probands is estimated by using the following formula: E ϭ ⌺ P i ϫ C i /N i (for i between 1 and 264), where P i , C i , and N i are the number probands, the number of CRC cases in the UPDB, and the number of persons in the UPDB, respectively, in the ith cohort group. This method assumes that the morbidity and migration rates for a given cohort of probands is on average the same as that for an equivalent cohort of persons in the UPDB.
For FRR ϭ O/E, P values were calculated, based on the null hypothesis FRR ϭ 1.0 and the alternative hypothesis FRR Ͼ1.0. An assumption was made that the number of observed cases followed a Poisson distribution with the mean equal to the expected number of cases. Confidence intervals for the FRRs were estimated by the method given by Agresti. 28 The selection of constellation patterns for which to calculate FRRs was based on common analyses in previous studies 11 and consensus of the authors. The first group of analyses performed in this study was based on systematically increasing numbers of relatives within each degree, for instance, calculating FRR for those with 1 affected FDR (irrespective of affected SDRs and TDRs), then 2 affected FDRs, then 3, and so forth. Because in a clinical setting individual patients are expected to have various degrees of family history knowledge, we calculated relative risks for the following situations: (1) only first-degree family history known, (2) only first-and second-degree family history known, and (3) first-, second-, and third-degree family history known. Additional constellation patterns and associated FRR estimates are contained in Supplementary Tables A and B (see supplemental material). Variations in age at diagnosis of CRC for the affected FDRs and SDRs (Supplementary Tables C  and D) were also considered. FRRs for Ն1 affected FDRs by type of FDR (eg, mother/father, brother/sister, parent/ sibling/child, offspring, and male/female) were estimated as well as the FRR for having both an affected mother and an affected father (Supplementary Table E) . We also estimated FRRs based on whether a proband's family history was concentrated solely on one side of a family versus both sides (Supplementary Table F) .
Results
A total of 2,327,327 persons included in Ն3 generation family histories were included in this analysis. Among these persons included in the study, 10,556 were identified with a primary diagnosis of CRC. On the basis of consensus among the authors, an FRR estimate Ն2.0 with the lower confidence interval Ͼ1.0 was considered a clinically relevant cutoff for elevated risk. All of the constellations producing FRR estimates meeting this clinically relevant criteria are presented in Tables 1-5 , along with selected others that are presented for comparison.
First-Degree Risk
The FRR estimates for probands with increasing numbers of affected FDRs, without respect to SDRs or TDRs, are shown in Table 1 . The most commonly published FRR is for Ն1 affected FDR. We estimated FRR ϭ 2.05 (95% CI, 1.96 -2.14) for probands with Ն1 affected FDR, similar to the meta-analysis FRR of 2.07 (95% CI, 1.89 -2.26) that was adjusted to account for suspected publication bias among source studies. 11
Second-Degree Risk
The FRR estimates for constellations with 0 or 1 affected FDRs and increasing numbers of affected SDRs are shown in Table 2 . A positive second-degree family history (in the absence of a positive first-degree family history) can be associated with increased risk, but does not appear to be of the same magnitude as a positive first-degree family history. Second-degree family history does appear to affect risk when combined with firstdegree family history. The FRR for 1 affected FDR with 1 affected SDR was 2.12 (95% CI, 1.90 -2.35), significantly higher than the FRR for 1 affected FDR and 0 affected SDRs (FRR, 1.82; 95% CI, 1.72-1.93; P ϭ .007). The FRR estimate for 1 FDR and Ն3 affected SDRs is even higher; FRR was 3.37 (95% CI, 2.20 -4.93) and in fact exceeds the estimated FRR for 2 affected FDRs.
Third-Degree Risk
For those probands with no affected relatives (FDRs, SDRs, TDRs) (N ϭ 1,460,367), FRR was 0.83 (95% CI, 0.81-0.86). Selected FRR estimates for constellations with 0 or 1 affected FDRs and various combinations of affected SDRs and TDRs are shown in Table 3 . A positive 
Age-Related Risk
Elevated FRR estimates based on the age of diagnosis of affected FDRs are shown in Table 4 . Typically disease onset Ͻ50 years is considered to be early for CRC, but we analyzed ages at diagnosis of 60 and 70 years as cutoffs as well. We estimated that for persons with Ն1 affected FDR diagnosed Ͻ50 years of age FRR was 3.31 (95% CI, 2.79 -3.89); this is significantly higher than the estimate for Ն1 affected FDR when the age of diagnosis was Ն50 (FRR ϭ 2.02; 95% CI, 1.93-2.11; P Ͻ .001). However, when the diagnosis age (of affected FDRs) was limited to between 60 and 69 years of age, the FRR estimate of 2.22 (95% CI, 2.04 -2.40) was still elevated above the chosen cutoff. In fact, it was significantly higher (P ϭ .045) than the FRR for probands with Ն1 affected FDR when the age of diagnosis was not considered (FRR ϭ 2.05; 95% CI, 1.96 -2.14), although for counseling purposes these numbers are not dissimilar.
When considering SDRs, age of diagnosis of the affected relative also affects risk. The FRR estimate for Ն1 affected SDR (without respect to FDRs and TDRs) was 1.27 (95% CI, 1.22-1.33). The estimate for Ն1 affected SDR diagnosed Ͻ50 years of age (FRR ϭ 1.84; 95% CI, 1.61-2.09) was significantly higher (P Ͻ .001).
Relationship Type-and Sex-Related Risks
We also estimated FRRs for specific FDR relationship types, shown in Table 5 . No difference was found between FRRs for those with an affected parent versus an affected sibling. Differences between FRRs estimated for persons with affected brothers and sisters and for persons with affected mothers and fathers were also not significant. A statistically significant difference (of small magnitude) was observed between female and male probands with Ն1 affected FDR, with such females having FRR ϭ 2.12 (95% CI, 2.00 -2.26) versus FRR ϭ 1.96 for males (95% CI, 1.84 -2.09; P ϭ .04). Of particular interest, and not previously published, was the risk estimate for those with both an affected mother and an affected father (FRR ϭ 4.97; 95% CI, 2.72-8.34). This is increased, although not quite significantly (P ϭ .07), over the FRR for Ն2 affected FDRs when probands with both an affected mother and father are excluded (FRR ϭ 3.21; 95% CI, 2.87-3.58). This rather rare occurrence may represent the situation of Ͼ1 predisposing genes segregating in the offspring of the 2 affected parents. Therefore, we also investigated FRRs for a pattern of family history involving cases on both sides of the family versus cases on one side of the family only. To examine this issue, we compared FRRs for probands with Ն2 affected SDR relatives, separately for the case of Ն2 affected relatives on the same side of the family and then for Ն1 affected relative on each side of the family. We similarly made the comparison for probands with Ն2 affected TDRs, again separately for the case of Ն2 affected relatives on the same side of the family and then for Ն1 affected TDR on each side of the family. Results are shown in Supplementary Table F. We excluded all probands with any affected FDRs. In neither analysis was there any significant difference in the FRR estimates, whether the family history was one-sided or both-sided.
Discussion
The purpose of this study was to define risk estimates for CRC, based on family history data from a homogeneous, well-characterized population, to better assist physicians in determining CRC risk in their patients. We used a large genealogic and cancer registry resource, the UPDB, to calculate FRRs for various constellations of family history risk of CRC. Characteristics of the Utah population represented in the UPDB data include extended relationships, large family sizes, low outmigration, low-to-normal inbreeding, and a genetic composition similar to the US white population. Cancer records from the UCR, which are included in the UPDB data set, strictly define the disease of interest. Because the UPDB includes comprehensive statewide cancer records from the UCR, it is free of ascertainment and recall bias that might affect other studies that rely on interviews with probands to assess cancer in relatives. This lack of ascertainment bias is a particular strength of this resource. Many previous studies have shown increased CRC risks for relatives of affected persons. Although the more common FRR estimates such as Ն1 affected FDR that we report here are consistent with studies included in the meta-analysis of Butterworth et al, 11 generally our estimates are lower with tighter confidence intervals. These differences may be due to the larger number of persons included in our analysis and perhaps differences in the incidence of disease between our population and those in other studies. Utah has the lowest incidence of CRC in the United States for both men and women, 47.5 and 35.2 per 100,000, respectively. 1 In the meta-analysis of Butterworth et al 11 sibling risk (relative risk [RR] ϭ 2.79; 95% CI, 2.36 -3.29) was reported to be higher than parent-offspring risk (RR ϭ 2.07; 95% CI, 1.83-2.34), and the authors suggested that this may indicate the presence of recessive genetic factors causing a susceptibility to CRC. We found no such difference between sibling and parent-offspring risk, even though the numbers of probands with an affected parent or affected sibling included in the analysis were Ͼ31,000 and Ͼ47,000, respectively. The Utah study's populationbased approach avoids the challenges of combining studies with different methods and ascertainment bias as well as accumulating higher numbers of patients for analysis, thus making this study's results more robust.
Although we were limited in our ability to explore increased risk associated with whether Ն1 CRC predisposition genes had an opportunity to segregate in a pedigree, we only observed a clearly significant effect for persons with both mother and father affected. Having both an affected mother and affected father confers a higher degree of risk (FRR ϭ 4.97; 95% CI, 2.72-8.34) than having Ն2 affected FDRs (FRR ϭ 3.26; 95% CI, 2.92-3.63). Only a small number of probands had 2 affected parents (n ϭ 450), but this is an interesting result that may be worth exploring in other large population sets. The elevated FRR in persons with both parents affected could result from gene-gene interaction, gene-environment interaction, or a combination of both. Our other FRR comparisons for second-and third-degree family history from one side of the family versus from both sides of the family did not show any significant differences.
On the basis of the FRR estimate for having no affected FDRs, SDRs, or TDRs (FRR ϭ 0.83; 95% CI, 0.81-0.86), persons with no known family history have a mild but significant protection, as might be expected (given that our overall risk estimates for all groups considered must average 1.0). Because this risk estimate relies on information on current age of all FDRs, SDRs, and TDRs (information which would not be typically available in a clinical setting), clinical recommendations for persons with no known first-, second-, or third-degree positive family history should include standard risk estimates and screening recommendations based on their current age.
Increased numbers of affected FDRs influence risk much more than affected SDRs or TDRs. In fact, in the absence of a positive first-degree family history (ie, 0 affected FDRs) and considering both affected SDRs and TDRs (but not age of diagnosis in affected relatives) only 1 constellation had an FRR estimate that was significantly Ͼ1.0 in the CI (0 affected FDRs, 1 affected SDR, 2 affected TDRs; FRR ϭ 1.33, 95% CI, 1.13-1.55). However, we previously noted that when combined with positive first-degree family history, the presence of positive second-and third-degree family history can significantly increase risk.
Age at diagnosis of CRC in affected relatives contributes significantly to risk estimates. Although an age at diagnosis Ͻ50 years typically has been used as a cutoff for early onset, we have shown that even diagnosis between 60 and 69 years of age in affected FDRs increases risk equivalent to the level of an affected FDR without respect to age at diagnosis. Therefore, older age of onset in an FDR should not be viewed as reassuring to the patient. In addition, even the age of onset in SDRs (Ͻ50 years) can have an effect on the proband's risk (FRR ϭ 1.84; 95% CI, 1.61-2.09 versus FRR ϭ 1.27; 95% CI 1.22-1.33 for Ն1 affected SDR without respect to age at diagnosis).
Precisely how our findings can be applied to CRC screening recommendations has yet to be determined, but extrapolation from current guidelines appears to be of some benefit. In the most current CRC screening recommendations, family histories that represent a 2-to 3-fold increased risk (usually any FDR with CRC diagnosed at age Ͼ60 years) suggest that CRC screening, as recommended for the general population, is indicated. 29, 30 Specifically, this includes any one of the screening tools now used (annual fecal occult blood testing, sigmoidoscopy every 5 years, combination of the first 2, barium enema or computed tomographic colonography every 5 years, or colonoscopy every 10 years). The only difference in recommendations for persons with this level of familial risk is that they should start at age 40 years, rather than at age 50 years. This is because this group exhibits the same risk at age 40 years as the general population at age 50 years. Persons with a risk of Ն3-fold compared with the general population because of family history (included are those with an FDR diagnosed at age Ͻ60 years or 2 FDRs with CRC) are now recommended to have colonoscopy as the screening tool of choice, starting at age 40 (or 10 years younger than the earliest diagnosis in the family) and have repeat colonoscopy every 5 years thereafter. Colonoscopy findings may alter these recommendations.
In view of these widely accepted guidelines, we would suggest provisionally that constellations of family risk that result in approximately 2-fold increased risk or approximately Ն3-fold risk be screened accordingly. A brief set of rules that specify constellations that meet these criteria is presented in Table 6 . Those persons with a strong family history should always be considered for one of the inherited syndromes of CRC. Physicians should encourage persons with increased, but Ͻ2-fold, risk to be screened according to guidelines for average risk.
This study has provided evidence that the existence of affected extended relatives increases the risk of CRC in probands. However, clinicians may question whether many patients typically have valid family history information for relatives more distant than first-degree and whether the effort required to document and use this information in clinical practice is cost-and time-effective. With more people taking an interest in family history, and a growing number of electronic tools and standards for documenting and sharing family health histories, the collection and clinical use of data from patients on family health histories beyond the first-degree may be reasonable in the near future. 31, 32 With regard to the limitations of the study, these results may not be generalizable to other populations with different racial or ethnic compositions. The Utah population has been shown to be representative of the US white and Northern European populations. Other potential limitations include the reliance on appropriate cancer diagnosis coding and inability to capture relatives not represented in the UPDB genealogy or with cancer diagnosed outside the state or outside the UCR time period. We have not excluded persons from our analysis with familial forms of CRC such as hereditary nonpolyposis colorectal cancer because they may not be reliably identified; one may wonder if pedigrees containing persons with these conditions have skewed the risk estimates. However, in a previous UPDB study the number of persons meeting the Amsterdam I criteria was estimated to be small (65 of 9458 cases or 0.7% of the cases), and none of these persons had a histology indicating familial adenomatous polyposis syndrome. 24 Finally, we observed certain constellations in which the corresponding FRR estimates did not follow the anticipated trend. As an example from Table 3 , FRR was 2.37 (95% CI, 1.58 -3.43) for probands with 1 affected FDR, 2 affected SDRs, and 0 affected TDRs. For those with 1 affected FDR, 2 affected SDRs, and 2 affected TDRs, FRR was 2.70 (95% CI, 1.44 -4.62). However, for probands with 1 affected FDR, 2 affected SDRs, and 1 affected TDR, FRR was 1.98 (95% CI, 1.15-3.17). Although there is clearly a pattern of increasing FRR for increasing numbers of affected relatives, individual estimates were not always consistent with the trend, and small sample size may be a factor.
Conclusion
In summary, this study is unique in providing definitions of CRC risk based on first-, second-, and third-degree family history constellations that have not been reported previously. These risk estimates were based on computerized genealogy and cancer registry data for large numbers of persons from a well-defined population. We have demonstrated that, although influencing risk to a lesser extent than first-degree family history, positive second-and third-degree family histories can have a significant effect on a person's risk of CRC. We have also demonstrated how the age of cancer onset (estimated by age at cancer diagnosis) in relatives affects risk. We have provided a comprehensive set of supplemental tables that accommodate various degrees of family history knowledge, which can be used to more precisely define CRC risk.
With respect to future work, producing absolute risk calculations in real time from a person's family history constellation and current age based on the FRR estimates presented could be automated. A computerized CRC family history risk prediction tool could be created as part of a personal health record application or as a decision support component in an electronic health record. Although family history is an important risk factor for CRC, clinical, environmental, and behavioral factors are also important, but how they affect genetic susceptibility is uncertain. We are currently working to create a more comprehensive CRC risk prediction model based on a combined set of family history and clinical data for a subset of the persons included in this current study. It is hopeful that this will provide additional 
